146 related articles for article (PubMed ID: 29397868)
1. SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma.
Shen Q; Nam SW
BMB Rep; 2018 Feb; 51(2):57-58. PubMed ID: 29397868
[TBL] [Abstract][Full Text] [Related]
2. Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.
Shen Q; Eun JW; Lee K; Kim HS; Yang HD; Kim SY; Lee EK; Kim T; Kang K; Kim S; Min DH; Oh SN; Lee YJ; Moon H; Ro SW; Park WS; Lee JY; Nam SW
Hepatology; 2018 Apr; 67(4):1360-1377. PubMed ID: 29059470
[TBL] [Abstract][Full Text] [Related]
3. Circulating small extracellular vesicle-derived splicing factor 3b subunit 4 as a non-invasive diagnostic biomarker of early hepatocellular carcinoma.
Son JA; Weon JH; Baek GO; Ahn HR; Choi JY; Yoon MG; Cho HJ; Cheong JY; Eun JW; Kim SS
J Exp Clin Cancer Res; 2023 Oct; 42(1):288. PubMed ID: 37899451
[TBL] [Abstract][Full Text] [Related]
4. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma.
Liu Z; Li W; Pang Y; Zhou Z; Liu S; Cheng K; Qin Q; Jia Y; Liu S
EBioMedicine; 2018 Dec; 38():57-68. PubMed ID: 30391496
[TBL] [Abstract][Full Text] [Related]
5. Enabled homolog (ENAH) regulated by RNA binding protein splicing factor 3b subunit 4 (SF3B4) exacerbates the proliferation, invasion and migration of hepatocellular carcinoma cells via Notch signaling pathway.
Deng G; Luo Y; Zhang Y; Zhang J; He Z
Bioengineered; 2022 Feb; 13(2):2194-2206. PubMed ID: 35030977
[TBL] [Abstract][Full Text] [Related]
6. SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells.
Lee J; Seo G; Hur W; Yoon SK; Nam SW; Lee JH
Anticancer Res; 2020 Apr; 40(4):2033-2042. PubMed ID: 32234894
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
[TBL] [Abstract][Full Text] [Related]
8. Increased Copy Number of the Gene Encoding SF3B4 Indicates Poor Prognosis in Hepatocellular Carcinoma.
Iguchi T; Komatsu H; Masuda T; Nambara S; Kidogami S; Ogawa Y; Hu Q; Saito T; Hirata H; Sakimura S; Uchi R; Hayashi N; Ito S; Eguchi H; Sugimachi K; Maehara Y; Mimori K
Anticancer Res; 2016 May; 36(5):2139-44. PubMed ID: 27127115
[TBL] [Abstract][Full Text] [Related]
9. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
[No Abstract] [Full Text] [Related]
10. Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.
Wang H; Lekbaby B; Fares N; Augustin J; Attout T; Schnuriger A; Cassard AM; Panasyuk G; Perlemuter G; Bieche I; Vacher S; Selves J; Péron JM; Bancel B; Merle P; Kremsdorf D; Hall J; Chemin I; Soussan P
Hepatol Int; 2019 Jul; 13(4):454-467. PubMed ID: 31140152
[TBL] [Abstract][Full Text] [Related]
11. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
12. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.
Reis H; Pütter C; Megger DA; Bracht T; Weber F; Hoffmann AC; Bertram S; Wohlschläger J; Hagemann S; Eisenacher M; Scherag A; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA
Biochim Biophys Acta; 2015 Jun; 1854(6):641-50. PubMed ID: 25448011
[TBL] [Abstract][Full Text] [Related]
13. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions.
Wasfy RE; Shams Eldeen AA
Asian Pac J Cancer Prev; 2015; 16(11):4769-75. PubMed ID: 26107238
[TBL] [Abstract][Full Text] [Related]
14. Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems.
Attallah AM; Omran MM; Attallah AA; Abdelrazek MA; Farid K; El-Dosoky I
Int J Clin Oncol; 2017 Apr; 22(2):332-339. PubMed ID: 27864623
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for the early diagnosis of hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis.
He S; Zhang DC; Wei C
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):426-34. PubMed ID: 25746139
[TBL] [Abstract][Full Text] [Related]
17. Combined aberrant expression of N-Myc downstream-regulated gene 2 and CD24 is associated with disease-free survival and overall survival in patients with hepatocellular carcinoma.
Li B; Shao Q; Ji D; Li F; Guo X; Chen G
Diagn Pathol; 2014 Oct; 9():209. PubMed ID: 25338637
[TBL] [Abstract][Full Text] [Related]
18. Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinoma.
Tremblay MP; Armero VE; Allaire A; Boudreault S; Martenon-Brodeur C; Durand M; Lapointe E; Thibault P; Tremblay-Létourneau M; Perreault JP; Scott MS; Bisaillon M
BMC Genomics; 2016 Aug; 17(1):683. PubMed ID: 27565572
[TBL] [Abstract][Full Text] [Related]
19. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
20. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
